My title



Long-term Effects of Continuing Adjuvant Tamoxifen

by jmiller on December 21, 2012

 Findings:  “Among women with ER-positive disease, allocation to continue tamoxifen reduced the risk of breast cancer recurrence, reduced breast cancer mortality, and reduced overall mortality, particularly after 10 years rather than stopping at 5 years.  These results, taken together with results from previous trials of 5 years of tamoxifen treatment versus none, suggest that 10 years of tamoxifen treatment can approximately halve breast cancer mortality during the second decade after diagnosis.  Lancet, Dec.5th.  Click here  to read full-text.